Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: a systematic review and meta-analysis.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
entrez:
28
1
2023
pubmed:
29
1
2023
medline:
1
2
2023
Statut:
ppublish
Résumé
Cholangiocarcinoma (CCA) is the second most common liver cancer. Diabetes is a well-known risk factor; however, treatment with metformin has been reported to be protective for several cancers, but data on CCA are still sparse and heterogeneous. We performed this meta-analysis to investigate the role of metformin as a potential protective factor for CCA. In this systematic review and meta-analysis, we searched PubMed/MEDLINE and EMBASE databases, from the date of inception to November 2022, for studies analyzing CCA rate in patients taking metformin. Twenty-nine articles were initially identified, of which four were eligible and included in our systematic review and meta-analysis, from which we estimated the relative risk (RR). The rate of CCA was lower for diabetic patients taking metformin than diabetic patients without metformin intake when comparing two highest quality studies [RR, 0.38; 95% confidence interval (CI), 0.290-0.508; P < 0.001], and three studies with similar inclusion criteria (RR, 0.34; 95% CI, 0.51-0.35; P < 0.001) without significant statistical heterogeneity among them (I2 = 29.83%, P = 0,2326 and I2 = 35.08%; P = 0.2143, respectively). Our study demonstrated a significant impact of metformin in reducing the risk of CCA by nearly 62-66% in diabetic patients taking metformin.
Identifiants
pubmed: 36708293
doi: 10.1097/MEG.0000000000002503
pii: 00042737-202303000-00002
doi:
Substances chimiques
Metformin
9100L32L2N
Hypoglycemic Agents
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-247Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13:261–280.
Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 2016; 21:594–599.
Carnevale G, Carpino G, Cardinale V, Pisciotta A, Riccio M, Bertoni L, et al. Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells. Sci Rep 2017; 7:14419.
Barner-Rasmussen N, Pukkala E, Hadkhale K, Färkkilä M. Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. United European Gastroenterol J 2021; 9:1128–1135.
Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008; 48:308–321.
Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 2006; 391:499–510.
Saengboonmee C, Seubwai W, Wongkham C, Wongkham S. Diabetes mellitus: possible risk and promoting factors of cholangiocarcinoma: association of diabetes mellitus and cholangiocarcinoma. Cancer Epidemiol 2015; 39:274–278.
Simon TG, King LY, Chong DQ, Nguyen LH, Ma Y, VoPham T, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies. Hepatology 2018; 67:1797–1806.
Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020; 72:95–103.
Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57:69–76.
Schlesinger S, Aleksandrova K, Pischon T, Jenab M, Fedirko V, Trepo E, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol 2013; 24:2449–2455.
Saengboonmee C, Seubwai W, Lert-itthiporn W, Sanlung T, Wongkham S. Association of diabetes mellitus and cholangiocarcinoma: update of evidence and the effects of antidiabetic medication. Can J Diabetes 2021; 45:282–290.
Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 2006; 169:877–888.
Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011; 18:R125–R147.
Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer 2013; 20:R1–R17.
Chocarro-Calvo A, García-Martínez JM, Ardila-González S, De la Vieja A, García-Jiménez C. Glucose-induced β-catenin acetylation enhances Wnt signaling in cancer. Mol Cell 2013; 49:474–486.
Liu J, Liu W, Li H, Deng Q, Yang M, Li X, et al. Identification of key genes and pathways associated with cholangiocarcinoma development based on weighted gene correlation network analysis. PeerJ 2019; 7:e7968.
Di Matteo S, Nevi L, Overi D, Landolina N, Faccioli J, Giulitti F, et al. Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. Sci Rep 2021; 11:2557.
Buczyńska A, Sidorkiewicz I, Krętowski AJ, Zbucka-Krętowska M, Adamska A. Metformin intervention–a panacea for cancer treatment? Cancers 2022; 14:1336.
Pernicova I, Korbonits M. Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10:143–156.
Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, et al. Antitumor effect of metformin on cholangiocarcinoma: in vitro and in vivo studies. Oncol Rep 2015; 34:2987–2996.
Saengboonmee C, Seubwai W, Cha’on U, Sawanyawisuth K, Wongkham S, Wongkham C. Metformin exerts antiproliferative and anti-metastatic effects against cholangiocarcinoma cells by targeting STAT3 and NF-ĸB. Anticancer Res 2017; 37:115–123.
Saengboonmee C, Seubwai W, Pairojkul C, Wongkham S. High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation. Sci Rep 2016; 6:18995.
Jiang X, Ma N, Wang D, Li F, He R, Li D, et al. Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. Oncotarget 2015; 6:3178–3194.
Ling S, Xie H, Yang F, Shan Q, Dai H, Zhuo J, et al. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. J Hematol Oncol 2017; 10:59.
Wandee J, Prawan A, Senggunprai L, Kongpetch S, Tusskorn O, Kukongviriyapan V. Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway. Life Sci 2018; 207:172–183.
Casadei-Gardini A, Filippi R, Rimini M, Rapposelli IG, Fornaro L, Silvestris N, et al. Effects of metformin and vitamin D on clinical outcome in cholangiocarcinoma patients. Oncology 2021; 99:292–299.
Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 372:n160.
Critical Appraisal Skills Programme. CASP qualitative studies checklist. 2018. https://casp-uk.net/casp-tools-checklists/ .
Perera R, Heneghan C. Interpreting meta-analysis in systematic reviews. Evid Based Med 2008; 13:67–69.
Tseng C-H. Metformin and biliary tract cancer in patients with type 2 diabetes. Front Oncol 2020; 10:587666.
Chaiteerakij R, Yang JD, Harmsen WS, Slettedahl SW, Mettler TA, Fredericksen ZS, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 2013; 57:648–655.
Sookaromdee P, Wiwanitkit V. Decreased risk of cholangiocarcinoma in diabetic patients treated with metformin. J Can Res Ther 2020; 16:82.
Marcano-Bonilla L, Schleck CD, Harmsen WS, Sadr-Azodi O, Borad MJ, Patel T, et al. Aspirin, statins, non-aspirin NSAIDs, metformin, and the risk of biliary cancer: a Swedish population-based cohort study. Cancer Epidemiol Biomarkers Prev 2022; 31:804–810.
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018; 15:95–111.